{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-057782","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.049972+00:00","generated_at":"2026-06-02T20:43:59.606417+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging","bullets":["Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer shows encouraging preliminary data; FDA Fast Track granted.","NXP900 preclinical data at AACR: robust activity in NSCLC cell lines; synergy with alectinib and osimertinib.","R&D expense $2.7M (+$0.3M YoY); G&A $1.7M flat; interest income $0.2M (vs $0.1M).","Several clinical data updates expected in 2H 2024; cash runway estimated into 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-057782","json":"https://secwatch.observer/filing/0001104659-24-057782.json","markdown":"https://secwatch.observer/filing/0001104659-24-057782.md","text":"https://secwatch.observer/filing/0001104659-24-057782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/0001104659-24-057782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/tm2413597d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:43:59.606417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"343ec6b0bded5a9f0804d645275b4cb513dff6c0","claim":"Nuvectis Pharma, Inc. reported first quarter ended March 31, 2024 results: net income $4.2 million.","evidence_excerpt":"First Quarter 2024 Financial Results Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023. The increase of $0.4 million in the cash balance in the first quarter of 2024 is a result of the utilization of the at-the-market facility, partially offset by the operating expenses for the quarter. The Company's net loss was $4.2 million for the three months ended March 31, 2024, compared to $4.0 million for the three months ended March 31, 2023, an increase in net loss of $0.2 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/0001104659-24-057782-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$4.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}